3[3]Food and Drug Administration. Federal Register, vol.63, no. 147, 31 July 1998. Available at URL: http://www. fda. org/cber/genadmin/351biol. text. 21 C. F.R Part 600 被引量：1
4[4]Karber G. Beitrag zur kollekiven behandlung pharmakologischer reihenversuche. Arch Exp Pathol Pharmakol, 1931; 162:480 被引量：1
5[5]Doel T R, Willams L, Barnett P V. Emergency vaccine against foot-and-mouth disease: rate of development of immunity and its implications for the carrier state. Vaccine, 1994;12:592-600. 9[9] Cox SJ, Barnett PV, Salt JS. Emergency vaccination of sheep against foot-andmouth disease: protection against disease and reduction.in contact transmission [J]. Vaccine, 1999; 17: 1858～1868 被引量：1
6[6]Barmett P V, Pullen L, Williams L, et al. International bank for foot-and -mouth disease vaccine: assessment of Montanide 1SA 25 and 206, two commercially available oil adju,ants[J]. Vaccine, 1996 ; 14 ; 1187～1198 被引量：1
7[7]Doel T R, Pullen L. International bank for foot-andmouth disease vaccine: stability studies with virus concentrates and vacines propared from them[J]. Vaccine,1990; 8:473～478 被引量：1
8[8]Samina 1, Zakay-Rones Z, Peleg B A. Homologous and heterologous antibody response of cattle and sheep after vaccination with foot and mouth disease and influenza virus[J]. Vaccine, 1998; 16:551～557 被引量：1
9[9]Samina I, Zakay-Rones Z, Weller J, et al. Host factors affecting the homologous and heterologous immune response of cattle to FMDV: genetic background, age,virus strains and route of administration [J]. Vaccine,1998; 16:335～339 被引量：1
10[10]Salt J S. Williams L, Barett P V, et al. Further studies on the rate of development of protection in cattle given emergency vaccination against FMD. Repots,Session of the Research Group of the Standing Technical Committee of the European Commission for the Control of foot-and-mouth Disdase and the foot-andmouth Disease Sub-group of the Scientific veterinary Committee of the Commission of the European Community, Modeling. 1995, Appendix 17. P. 90～97 被引量：1
